Zobrazeno 1 - 10
of 527
pro vyhledávání: '"Shokhin, A."'
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 208-215 (2024)
Introduction. Adalimumab, a fully humanized monoclonal antibody, is a tumor necrosis factor (TNFα) inactivator that is used against a number of autoimmune diseases such as rheumatoid arthritis and other most common inflammatory arthropathies (ankylo
Externí odkaz:
https://doaj.org/article/61c7f9e522ba49819af0b0a58b6b54e9
Publikováno v:
Научно-практическая ревматология, Vol 62, Iss 1, Pp 104-108 (2024)
The aim of the study – to evaluate the effectiveness of the drug Alflutop (bioactive concentrate of small marine fish), as well as its effect on microcirculation parameters in patients with osteoarthritis (OA) of small joints of the hands.Patients
Externí odkaz:
https://doaj.org/article/1a8d71f6d37c4759bf385fb4750a69b1
Publikováno v:
Современная ревматология, Vol 18, Iss 1, Pp 84-89 (2024)
A patient with a subacute course of systemic sclerosis (SSc) and a three-phase Raynaud's phenomenon at the onset of the disease is described. The diagnosis was made in accordance with the ACR/EULAR 2013 criteria. Within 8 months of disease onset, the
Externí odkaz:
https://doaj.org/article/d51a90dfdca14df8bdac73edb7fe989c
Autor:
A. S. Ametov, I. E. Shokhin, E. A. Rogozhina, T. G. Bodrova, M. E. Nevretdinova, P. A. Bely, K. Ya. Zaslavskaya, V. S. Scherbakova, D. V. Kurkin, K. N. Koryanova, E. S. Mishchenko, E. Yu. Kesova, E. D. Kozlov, E. S. Samoshkina, D. N. Andreev, Yu. G. Kazaishvili, S. M. Noskov, L. A. Balykova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 4, Pp 324-346 (2024)
Semaglutide is a representative of analogues of the incretin hormone human glucagon-like peptide-1 (GLP-1) and is currently used in Russia for the treatment of type 2 diabetes mellitus (T2DM; in monotherapy and in combination therapy), including pati
Externí odkaz:
https://doaj.org/article/c34ff57fdc98416a8dce0a84dbcfc85b
Autor:
I.V. Shokhin
Publikováno v:
Кавказский энтомологический бюллетень, Vol 20, Iss 1, Pp 89-91 (2024)
The nominotypical subgenus of the genus Anisoplia Schönherr, 1817 contains over 50 species, nine of which are known in the European Russia: A. agricola Poda von Neuhaus, 1761, A. brenskei Reitter, 1889, A. deserticola Fischer von Waldheim, 1824, A.
Externí odkaz:
https://doaj.org/article/956500861d984d2fa18d90f4634f7b22
Autor:
A. S. Ametov, I. E. Shokhin, E. A. Rogozhina, T. G. Bodrova, M. E. Nevretdinova, P. A. Bely, K. Ya. Zaslavskaya, D. V. Kurkin, K. N. Koryanova, E. S. Mishchenko, S. M. Noskov
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 3, Pp 255-276 (2023)
Liraglutide is one of the analogues of the incretin hormone human glucagon-like peptide-1 (GLP-1) and is currently a priority treatment for diseases such as type 2 diabetes mellitus (mono- and combination therapy), obesity and overweight in the prese
Externí odkaz:
https://doaj.org/article/2594ff78904340c69eb6d062f929ba86
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 3, Pp 240-249 (2023)
Introduction. Trastuzumab is the first drug based on the monoclonal antibodies’ technology targeted to the neu oncogene expression product discovered in the middle 80-s – human epidermal growth receptor, HER2. After being approved trastuzumab had
Externí odkaz:
https://doaj.org/article/60567173043c4434badf112989e98f06
Autor:
A. N. Arevefa, A. R. Dorotenko, S. M. Noskov, I. E. Makarenko, R. V. Drai, T. N. Komarov, O. A. Archakova, N. S. Bagaeva, I. E. Shokhin
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 3, Pp 218-227 (2023)
Introduction. Citicoline is an endogenous nucleoside consisting of cytidine and choline linked by a diphosphate bridge that is involved in the synthesis of membrane phospholipids. Drugs containing citicoline have neuroprotective and neurometabolic ef
Externí odkaz:
https://doaj.org/article/ccf7fc38cfed460b835470037a54f63e
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 2, Pp 190-197 (2023)
Introduction. Trastuzumab is the first known anti-HER2 agent, which revolutionized the treatment of one of the most common cancer types – breast cancer. Despite trastuzumab being approved long time ago, further improvement of related analytical met
Externí odkaz:
https://doaj.org/article/0b11890d05ed48ffb34039204a4094fd
Autor:
Averbakh, Leopol’d, author, Shokhin, An., author, Treivas, B., author, Pen’kov, N., author, Dalin, V., author, Fedorov, M., author, Dugachev, M., author, Deliusin, F., author, Bezymenskii, A., author
Publikováno v:
Trotsky’s Challenge: The ‘Literary Discussion’ of 1924 and the Fight for the Bolshevik Revolution. 114:481-484